| Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. | |
| | |
MedLine Citation:
|
PMID: 18550578 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Positron emission tomography (PET) is more accurate than computed tomography (CT) in staging and restaging of lymphoma, but both are considered necessary. Increasingly, PET is carried out with a low-dose CT scan. Many patients undergo both PET/CT and standard diagnostic CT. The clinical utility of performing both studies in patients with lymphoma was evaluated. PATIENTS AND METHODS: Patients with lymphoma who underwent concurrent PET/CT and diagnostic CT (a scan pair) were identified, and findings detected in either scan but not both were documented. Discrepancies were considered significant if they were related to either lymphoma or another disease process which potentially required intervention. RESULTS: Eighty-seven scan pairs were identified. PET/CT detected additional lesions over diagnostic CT in 30 patients, of which 11 demonstrated increased clinical stage. Lymphoma therapy changed based on PET/CT in two patients, and one occult rectal cancer was detected. In contrast, diagnostic CT detected five relevant findings, including two incidental findings (venous thrombosis) and three patients with splenic lesions, none of which could be confirmed as lymphoma. No patient had change of stage or lymphoma therapy based on diagnostic CT. CONCLUSION: In our series, diagnostic CT did not add value to staging or restaging of lymphoma when carried out concurrently with PET/CT. |
| | |
Authors:
|
R L Elstrom; J P Leonard; M Coleman; R K J Brown |
Related Documents
:
|
18852078 - Pet/ct for staging and monitoring non small cell lung cancer. 16467718 - Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients... 17059628 - Should fdg-pet scanning be routinely used for patients with an unknown head and neck sq... 15717948 - Functional imaging in head and neck cancer. 22543768 - The ureter as a landmark for robotic sacrocolpopexy. 21111458 - Renal tissue ablation with irreversible electroporation: preliminary results in a porci... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2008-06-10 |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: 19 ISSN: 1569-8041 ISO Abbreviation: Ann. Oncol. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-23 Completed Date: 2008-10-30 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 1770-3 Citation Subset: IM |
Affiliation:
|
Division of Hematology-Oncology, Department of Medicine, Center for Lymphoma and Myeloma Weill Cornell Medical College and the New York Presbyterian Hospital, New York, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Fluorodeoxyglucose F18
/
diagnostic use Humans Lymphoma / diagnosis*, pathology, radionuclide imaging Neoplasm Staging Positron-Emission Tomography / methods Radiopharmaceuticals / diagnostic use Retrospective Studies Tomography, X-Ray Computed / methods |
| Grant Support | |
ID/Acronym/Agency:
|
K08 HL070827/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4)...
Next Document: Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.